NRX Pharmaceuticals, Inc. 8K

NRx Pharmaceuticals reported Q2 2026 results and announced significant regulatory, clinical, strategic, and financing milestones, including progress toward FDA approval and commercialization of preservative‑free ketamine, DARPA‑funded NRX‑101 trials, and a $22.3 million equity offering that extends its cash runway for at least one year.

On August 17, 2026, NRx Pharmaceuticals, Inc. reported its financial results for the quarter and six months ended June 30, 2026 and provided a corporate and pipeline update, highlighting completion of the first‑cycle FDA review of its ANDA for preservative‑free ketamine with no drug‑related major deficiencies and submission of the remaining vial attestation, initiation of commercial‑scale manufacturing to build launch stock of 5 million doses targeting a 2026 launch, continued advancement of the NRX‑100 NDA for depression using Real World Evidence from more than 65,000 patients with an approval goal in 2027, selection by DARPA as prime contractor for the SPARC‑TMS Phase 2/3 trial of NRX‑101 with anticipated non‑dilutive funding of more than $11.5 million, investment in and acquisition of GeNeuro assets to develop monoclonal antibodies for ALS, schizophrenia, multiple sclerosis, and type 1 diabetes, the closing of an underwritten public offering of common stock for gross proceeds of approximately $22.3 million that increased cash to $26.7 million and is expected to fund operations for at least one year, and the expansion of its HOPE Therapeutics clinical network plus appointment of a Chief Commercial Officer ahead of anticipated commercial launch.

Filing Facts

CIK

1719406

Ticker

-

Form

8K

Source Type

sec

Accession

0001437749-26-028111

Alert Tier

7